6/29/26….We will update SMID cap biotechs tomorrow but you should review our January summary post after the JPMorgan Healthcare Conference.
6/27/26 ,,,Update-4: A Big Week for Biotech and Healthcare in a down market with the XLK down 5.4%.
- XBI up 10.4%, IBB up 7.6%, XLV up 7.3%, ARKG up 12.4%.
- Hot stocks in XLV (Healthcare) for the week: Bio Techne (TECH) up 22.4%, Abbvie (ABBV) up 17%, Incyte (INCY) up 15.8%, Merck (MRK) up 12.99%,JNJ (JNJ) up 11.5%,Baxter INTL(BAX) up 10.8%.
- New buys : Agllent Technologies (A), Baxter (BAX), Abbott (ABT), GE Healthcare (GEHC).
- SMID BIOTECH stocks most notable holds: PSNL up 23.53%, XNCR up 19%, NTRA up 13%,GH up 13%, ILMN up 9%.
========
6/24/26..1045a. EDT….UPDATE 3: Rally continues broadly into healthcare and biotech with XBI over 2% to $150 level. Movers ILMN up 6.65%, NTRA up 8%.
6/23/26 Rotation into Healthcare-day 2 -XLV up 1.41% to $152 led by Biotech stocks with XBI up 0.85 to $147.03.
- Large cap leaders: JNJ, MRK, NVS, ABBV, AZN, RHHBY.
- MedTECH Catches a few bids: ABT up 3.07%,BDX up 2.28%, GEHC up 5.08%.
- SMID Biopharma 3%+movers: AMRX,EYPT, PTGX, RCUS, RYTM, SLDB.
- Favorite stocks to watch on upcoming earnings in JULY:Illumina (ILMN) up 2.2%, Natera (NTRA), up 2.6%.
Biotech Stocks Gain Momentum in a Major Rotation
- SMID Biotech Stocks as tracked by the XBI are up 3.65% on Monday and close to a new FIVE year high
- Abbvie bolsters Immunology Portfolio with acquisition of Apogee Therapeutics for about $10.9B.
- Broad momentum in many SMID biotechs portend a good week.
TECHNOLOGY stocks are exhausted and taking a rest today as biotech stocks get some deserved attention. Our SMID Trading list showed a lot of green screen helped by the XBI breaking out up 3.65% to $145.86. The equal weighted small cap State Street SPDR S&P Biotech ETF(XBI) is up 10.79% over 4 weeks and 19.63% YTD. The IBB was also up 1.94% YTD and the iWM helped up 0.88%.
Many of our SMID Biotech picks gained strength: ABSi up 13.36%, COGT up 3.76%, DNTH up 5.92%, PTCT up 2%, PTGX up 1.92%, RCUS up 12%, RNAC up 3.3% and Xencor (XNCR) up 10.84%. There was no news on XENCOR but with a Market Cap of about $1B and a strong cash position of $6/sh and a broad pipeline of clinical stage engineered antibodies for cancer and autoimmune disease prospects look good for a partner or milestone data.
Abbvie (ABBV) gained 6.25% on news of the acquisition of Apogee Therapeutics strengthening their portfolio of anti-inflammatory products for atopic dermatitis and asthma. Abbvie’s current immunology portfolio includes $7.3Bin sales from Q1 including drugs Skyrizi and Rinvoq.
We will update many of our SMID trading stocks this week so stay tuned. AS of 10:20a EDT many of our SMID biotech stocks are up 2% and more. There IBB is up 4% over 5 days.
